Moneycontrol PRO

business

See Ipca FY16 EPS at Rs 37 despite FDA heat: Religare Cap

Arvind Bothra of Religare Capital Markets doesn't see US FDA action against Ipca translating into a similar action by European or other regulators because they have definitely different norms etc.

first published: Nov 5, 2014 12:45 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347